Myriad Genetics (MYGN) Tops Q3 EPS by 8c
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $4.54 --0%
Revenue Growth %: -2.7%
Financial Fact:
Selling, general, and administrative expense: 111.9M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -2.7%
Financial Fact:
Selling, general, and administrative expense: 111.9M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.06), $0.08 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $173.1 million versus the consensus estimate of $156.2 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight
- AbbVie agrees to acquire Apogee Therapeutics for $10.9 billion
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
